Posted inClinical Updates news Oncology
Long-Term Survival Following Cytoreductive Surgery and HIPEC for Pseudomyxoma Peritonei: Insights from a 22-Year Single Institution Experience and Contemporary Evidence Synthesis
22-year single-center data confirm CRS and HIPEC as safe, effective for PMP, yielding 62% 5-year survival. Prognostic factors, optimized HIPEC regimens, and perioperative management impact outcomes and recurrence.
